Suppr
超能文献

Durability of Bivalent Boosters against Omicron Subvariants.

作者信息

Lin Dan-Yu, Xu Yangjianchen, Gu Yu, Zeng Donglin, Sunny Shadia K, Moore Zack

机构信息

University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC

North Carolina Department of Health and Human Services, Raleigh, NC.

出版信息

N Engl J Med. 2023 May 11;388(19):1818-1820. doi: 10.1056/NEJMc2302462. Epub 2023 Apr 12.

DOI:10.1056/NEJMc2302462

PMID:37043647

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10120009/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309e/10120009/861e3baef65e/NEJMc2302462_f1.jpg

相似文献

Durability of Bivalent Boosters against Omicron Subvariants.

N Engl J Med. 2023 May 11;388(19):1818-1820. doi: 10.1056/NEJMc2302462. Epub 2023 Apr 12.

mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.

bioRxiv. 2022 Nov 1:2022.10.31.514636. doi: 10.1101/2022.10.31.514636.

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations.

Vaccines (Basel). 2023 Apr 27;11(5):906. doi: 10.3390/vaccines11050906.

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.

Microbiol Spectr. 2023 Mar 22;11(2):e0513122. doi: 10.1128/spectrum.05131-22.

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.

Nat Commun. 2023 Sep 27;14(1):6041. doi: 10.1038/s41467-023-41678-9.

Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.

J Med Virol. 2023 Jan;95(1):e28279. doi: 10.1002/jmv.28279. Epub 2022 Nov 11.

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.

Vaccines (Basel). 2023 Aug 4;11(8):1320. doi: 10.3390/vaccines11081320.

The Omicron-transformer: Rise of the subvariants in the age of vaccines.

Ann Acad Med Singap. 2022 Nov;51(11):712-729. doi: 10.47102/annals-acadmedsg.2022294.

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study.

Hum Vaccin Immunother. 2023 Aug 1;19(2):2242217. doi: 10.1080/21645515.2023.2242217.

Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants.

Microorganisms. 2023 Sep 18;11(9):2336. doi: 10.3390/microorganisms11092336.

引用本文的文献

Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.

Hum Vaccin Immunother. 2025 Dec;21(1):2502250. doi: 10.1080/21645515.2025.2502250. Epub 2025 May 16.

Systemic and Mucosal Antibody Responses to SARS-CoV-2 Variant-Specific Prime-and-Boost and Prime-and-Spike Vaccination: A Comparison of Intramuscular and Intranasal Bivalent Vaccine Administration in a Murine Model.

Vaccines (Basel). 2025 Mar 25;13(4):351. doi: 10.3390/vaccines13040351.

Long term bivalent mRNA vaccine effectiveness against COVID-19 hospitalisations and deaths in Portugal: a cohort study based on electronic health records.

BMC Infect Dis. 2025 Apr 23;25(1):590. doi: 10.1186/s12879-025-10866-x.

Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge.

PLoS Pathog. 2025 Apr 21;21(4):e1012585. doi: 10.1371/journal.ppat.1012585. eCollection 2025 Apr.

Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23.

Epidemiol Infect. 2025 Mar 17;153:e54. doi: 10.1017/S0950268825000317.

Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA.

BMJ Open. 2025 Feb 22;15(2):e084408. doi: 10.1136/bmjopen-2024-084408.

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.

NPJ Vaccines. 2025 Jan 10;10(1):4. doi: 10.1038/s41541-025-01062-8.

Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States.

J Infect Dis. 2025 Apr 15;231(4):e743-e753. doi: 10.1093/infdis/jiaf007.

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.

Vaccines (Basel). 2024 Dec 16;12(12):1418. doi: 10.3390/vaccines12121418.

Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.

Microorganisms. 2024 Dec 14;12(12):2591. doi: 10.3390/microorganisms12122591.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Durability of Bivalent Boosters against Omicron Subvariants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译